By Ted Mathias, Stacie Ropka and Nisan Zaghi (October 26, 2018, 3:44 PM EDT) -- The Biologics Price Competition and Innovation Act of 2009 outlines a series of steps, commonly referred to as the "patent dance," for resolving patent disputes involving biologic drugs. The patent dance is similar in some respects to the now-familiar Orange Book listings and notice letters that precede a Hatch-Waxman litigation for small molecule drugs. The patent dance is different, however, in that parties face more strategic choices. Whereas the presuit Hatch-Waxman process is essentially mandatory, an abbreviated biologic license applicants might elect to forgo the patent dance.[1] For parties that do engage in the patent dance, recent litigations for the antibodies trastuzumab and adalimumab point to the different approaches parties can take....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
